Medicare faces a June 15 deadline on TAVR coverage. Behind the policy: a $9M annual registry fee stream controlled by cardiology and thoracic surgery societies.
Alpha Score of 53 reflects moderate overall profile with moderate momentum, moderate value, weak quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
By June 15, Medicare is expected to announce a coverage decision that will determine whether millions of seniors can access transcatheter aortic valve replacement (TAVR) without the burdensome restrictions that have governed the procedure since 2012. The decision will also determine whether a $9 million annual fee stream – controlled by two professional medical societies – remains mandatory.
The policy in question is Coverage with Evidence Development (CED). Under CED, the Centers for Medicare & Medicaid Services (CMS) denies routine coverage for an FDA-approved treatment unless the patient is enrolled in a clinical study or registry. For TAVR, that means a patient must schedule separate appointments with a surgeon and a cardiologist, the surgeon must be paid to be present during the procedure, the hospital must enroll in the STS-ACC TVT Registry, and the site must meet annual procedural volume thresholds.
CED was designed to collect real-world data on new technologies. For TAVR, it has generated more than 1 million registry patients and 20,000 published articles. The policy also created a gatekeeping structure that controls where and how quickly patients get treated.
Joe Grogan, Nonresident Senior Scholar at the USC Schaeffer Institute and a former Domestic Policy Council director under President Trump, framed the tension directly: "The evolution in heart valve treatment since 2011 not only impacts patients but the ecosystem of hospitals and specialty physicians who make a living treating these conditions."
The key players are the Society for Thoracic Surgeons (STS) and the American College of Cardiology (ACC). These two professional societies jointly govern the TVT Registry, which is mandatory for every TAVR site.
Before TAVR was approved in 2011, thoracic surgeons were the default providers for aortic valve replacement. Open-heart surgery required stopping the heart, bypass, and a long recovery. TAVR, performed by interventional cardiologists, eliminated the chest incision and cut recovery time sharply. The surgeons faced an existential revenue threat.
The STS and ACC responded by advocating for Medicare to impose a CED policy in 2012. The specific requirements go beyond data collection:
Practical rule: When a policy forces a competing specialist to be in the room and paid, the clinical rationale and the financial rationale are hard to separate.
The TVT Registry is not free. Hospitals pay $25,000 to set up and $10,500 per year per facility. With about 860 qualified TAVR sites, that generates roughly $9 million in annual fees before adding revenue from manufacturers and researchers who buy data access.
Those costs are absorbed by large heart centers but are often prohibitive for smaller community hospitals and rural programs. The result is geographic concentration: TAVR access depends on where you live.
USC Schaeffer Center research shows that patients in rural areas are underrepresented at TAVR hospitals and typically cannot access the procedure closer to home. A 2024 study found that patients treated more than ninety days after diagnosis face a 50% higher risk of death over three years and nearly $37,000 in additional health care costs compared to those treated promptly. The CED requirements themselves add an average 59 days between diagnosis and treatment.
Key insight: The registry does not just collect data – it creates a fixed cost barrier that disproportionately affects lower-volume and rural sites, locking the access pattern in place.
When the CED was written, CMS accepted the argument that annual procedural volume was a reasonable surrogate for quality. The logic: if a hospital does more heart surgeries, it will be better at TAVR.
Dr. Peter Pelikan, MD, FACC, FSCAI, Medical Director of the Cardiac Catheterization Laboratory at Saint John's Hospital, challenged that logic in 2017 when he and two other interventional cardiologists wrote to CMS requesting reconsideration. "The rationale for the annual procedural volume requirements when the CED started was 'if you do more of something you must be better at it,'" Pelikan said. "There is no relationship between performance of surgery or other interventional cardiac procedures and TAVR. The analogy would be if I do 100 hernias on you, does that mean I can replace your hip?"
Research has since confirmed that volume never was a valid surrogate. Analyses of TVT Registry data show that outcomes have improved across all volume levels as TAVR became routine. The performance gap between high- and low-volume programs has narrowed to statistical insignificance for most measures.
Grogan put it directly: "The procedural volume requirements that the societies advocated for have been invalidated by the TVT registry data that they manage."
Despite that, CMS has no direct access to the registry data. The last annual report of aggregate registry data was published six years ago and covers patients only through 2019. CMS also has no enforcement mechanism to ensure the CED research questions are answered and shared publicly, as required by law.
The combination of mandatory separate appointments, surgeon presence requirements, and registry enrollment creates a clinical bottleneck. For a symptomatic patient with severe aortic stenosis, the 59-day delay is not a paperwork issue – it is a mortality risk. The USC research quantifies that risk precisely: a 50% higher three-year death rate if treatment comes after ninety days.
Rural patients are not only delayed but also less likely to be treated at a TAVR-capable hospital in the first place. The registry's fixed costs and volume requirements discourage smaller hospitals from entering the market, leaving large urban centers as the only option for patients who may not be able to travel.
Kelly Cleary, Partner at Akin and former HHS Deputy General Counsel and CMS Chief Legal Officer in the first Trump administration, raised a legal question: "Can CMS plausibly say that after 14 years of 'evidence development' there is still insufficient evidence that TAVR is reasonable and necessary for Medicare coverage purposes? Data has been collected for over a decade, and TAVR is the standard of care. Willful ignorance of decades of evidence is the very antithesis of the reasoned decision making required of agencies under the Administrative Procedure Act."
If CMS retains the CED requirement after June 15, the agency will need to justify why 1 million patients and 20,000 articles are not enough. If it drops the CED, the STS-ACC Registry will lose its mandatory status, and the $9 million annual fee stream will likely shrink.
In May, the Alliance for Aging Research polled 1,000 U.S. adults. 77% said Medicare should cover TAVR the same way it covers open-heart surgery. 67% said they would be more likely to support a political candidate who "supports requiring Medicare to broaden patient access to TAVR." The numbers suggest the status quo has public opinion against it, the lobbying weight of the specialty societies is significant.
The clearest beneficiaries are thoracic surgeons. The surgeon-presence requirement guarantees that a surgeon is paid for every TAVR procedure, even if the role is supervisory. That payment stream is direct and material. If CED is eliminated, the surgeon's compensation for simply being in the room disappears.
Interventional cardiologists perform the procedure but must work within the registry framework. The ACC coordinates the comment letter among specialty societies, and its January 2026 submission strongly recommends continuation of the TAVR NCD under CED. The ACC declined to provide a quote and instead sent the letter, which was coordinated among the societies.
The registry also provides the societies with a data monopoly. Manufacturers and researchers pay for access to the data, which gives the STS and ACC a second revenue stream beyond hospital fees.
What this means: The TAVR CED policy creates a self-reinforcing financial loop – the societies set the rules, collect the fees, and control the data that CMS uses to evaluate whether the rules are still needed.
If CMS announces on June 15 that it will keep the CED requirement – possibly with minor modifications – the $9 million annual registry fee stream and the surgeon-presence payment will remain intact. Specialists who benefit from the current structure will see no change to their revenue. The rural access gap will persist. The 59-day delay will continue.
If CMS drops the CED, the mandatory registry enrollment requirement will be eliminated. Hospitals will still be able to participate voluntarily, the financial barrier for smaller sites will drop. That could increase the number of TAVR centers, reduce geographic disparities, and shorten the time from diagnosis to treatment. For heart specialists, it would end the surgeon-presence payment and reduce the societies' data revenue, it would also open the procedure to more interventional cardiologists in more settings.
The question for traders: there are no publicly traded companies directly exposed to the TAVR registry revenue itself. Device makers would benefit from broader access and faster adoption, the CED removal does not change their product approvals. The effect on those stocks is indirect and would depend on the volume response.
For physicians and hospital operators, the decision is binary. A retained CED means the status quo continues. A dropped CED means the competitive landscape for heart valve treatment shifts toward interventional cardiologists and away from the surgical monopoly that has controlled TAVR since 2012.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.